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In addition to their well-known antibacterial activity some antimicrobial peptides and proteins
(AMPs) display also antiviral effects. A 27 aa peptide from the N-terminal part of human
bactericidal/permeability-increasing protein (BPI) previously shown to harbour antibacterial
activity inhibits the infectivity of multiple Influenza A virus strains (H1N1, H3N2 and H5N1)
the causing agent of the Influenza pneumonia. In contrast, the homologous murine BPI-pep-
tide did not show activity against Influenza A virus. In addition human BPI-peptide inhibits
the activation of immune cells mediated by Influenza A virus. By changing the human BPI-
peptide to the sequence of the mouse homologous peptide the antiviral activity was
completely abolished. Furthermore, the human BPI-peptide also inhibited the pathogenicity
of the Vesicular Stomatitis Virus but failed to interfere with HIV and measles virus. Electron
microscopy indicate that the human BPI-peptide interferes with the virus envelope and at
high concentrations was able to destroy the particles completely.
Introduction
Influenza is a very common infectious disease and the causing agent Influenza A virus is a very
successful pathogen. It constantly circulates in many animal hosts, such as humans, pigs,
horses, dogs and birds. Annual epidemics of seasonal influenza result in millions of humans
worldwide infected. This causes a prominent health and economic risk [1]; influenza pandem-
ics can also have devastating effects globally, resulting in millions of deaths [2].
Influenza A virus (IAV) is an enveloped negative-sense single-stranded RNA-virus of the
orthomyxovirus family. Subtypes of IAV expressing different neuraminidase and
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hemagglutinin proteins are able to infect a variety of hosts. Hemagglutinin thereby interacts
with either α-2,3- or α-2,6-sialiated (SA) proteins and enters the cells via endocytosis [3] and
therefore determining host tropism. Thereafter, the endosome is acidified which results in the
fusion of the virus envelope with endosomal membrane releasing the viral genome into the
cytoplasm. Then the viral RNA-protein complex (RNP) translocates to the nucleus where the
negative RNA is either replicated into a positive RNA-strand or transcribed to mRNA by the
viral encoded RNA-dependent RNA-polymerase. After that the viral mRNAs leave the nucleus
and are exported to the cytoplasm for translation. This will most likely result in a total of 11or
12 viral proteins but the precise number of viral proteins is still under debate and might differ
in different host cells.
The budding of the progeny virus occurs via the neuraminidase activity of NA. These will
destroy the SA moieties of the cellular and the viral glycoproteins and free the active sites of the
viral proteins in the envelope to allow for a new infections cycle.
The nonstructural protein NS1 inhibits host interferon-mediated antiviral responses and
thus promotes the pathogenesis of IAV [4].
Today we know of 16 HA and 9 NA subtypes of IAV infecting birds. Recently, two addi-
tional subtypes of IAV which are bat-derived were identified. These subtypes were termed
H17N10 and H18N11, respectively [5,6]. These new findings raising the possibility of bats serv-
ing as a reservoir for new subtypes of IAV causing a possible thread of humans. In humans 2
subtypes circulate: H1N1 and H3N2 (H2N2 strains were also circulating in humans from 1957
to 1968). Overall, the HA subtypes are classified into two groups (or lineages) based on their
antigenic properties and their major structural features [7–10].
The infectivity of Influenza A virus is restricted by mechanisms of the innate immune
response to avoid the binding and/or invasion of the host epithelial cells especially in the lung.
One mechanism of the epithelial cells to avoid binding and/or invasion is by the action of anti-
microbial proteins and peptides (AMPs).
AMPs are crucial mediators of the innate immune system. In particular AMPs protect the
epithelial surfaces of the body and prevent the invasion of pathogens into the host organism.
The potency of AMPs against bacteria is well known and demonstrates that AMPs not only
interact with bacterial cell membrane to destroy bacteria [11].
Recently it was shown that some AMPs influence the infectivity of viruses as well. For exam-
ple the defensin cathelicidin blocks the replication of IAV in vitro and therefore the application
of cathelicidin protects mice against an infection with IAV in a prophylactic setting [12]. The
exact molecular mechanism of the antiviral effect of cathelicidin remains currently unknown.
Moreover the human α-Defensin human neutrophil peptide 1 (HNP-1) was shown to display
anti-HIV activity. HNP-1 inhibits the binding of the virus to its coreceptor (CCR5 und
CXCR4), the endocytosis of the virus into the target cell as well as the release of the HIV-
genome from the endosome into the cytoplasm. However HNP-1 did not inhibit the endocyto-
sis of Influenza A virus displaying some selectivity of the AMPs in their tropism [13]. These
results clearly demonstrate that defensins not only display antimicrobial activity but in addi-
tion are active against viruses as well.
Bactericidal/permeability-increasing protein (BPI) belongs to the class of AMPs. In contrast
to the above mentioned defensins BPI due to the 55 kDa molecular size of the protein is struc-
turally much more complex than the peptides, which are in the range of 3–5 kDa. The BPI pro-
tein family comprises of more than 10 members but only BPI itself displays a strong
antimicrobial activity. BPI acts bactericidal against gram negative bacteria, neutralizes bacterial
lipopolysaccharide (LPS) from the cell wall of gram negative bacteria and opsonizes bacteria if
bound to the bacterial cell wall. On the other hand the closely related protein lipopolysaccharide
binding protein (LBP) binds LPS with the same molecular moieties in comparison to BPI. This
BPI and Influenza
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binding however results in the recognition of LPS by the immune system [14]. Recently the pal-
ate, lung, and nasal epithelium clone associated proteins (PLUNCs) were added to the BPI pro-
tein family. The PLUNC subfamily is not closely related to BPI on the primary amino acid
sequence level. However computational predictions of the protein structure of these proteins
reveals a surprising similarity with BPI and LBP. The PLUNC proteins are divided into short
(S) and long (L) PLUNC proteins. SPLUNCs are homologous to the N-terminal part of BPI
whereas LPLUNC proteins are homologous to the complete BPI protein. All PLUNC proteins
are expressed in the nasopharyngeal cavity and only SPLUNC1 and LPLUNC1 are found to be
expressed in the respiratory system. SPLUNC1 is synthesized by epithelial cells of the upper
respiratory tract and LPLUNC1 is associated with goblet cells in the proximity of ciliated epi-




The local ethics committees of Justus-Liebig-University Giessen (Ethikkommission des Fach-
bereichs Medizin der Justus-Liebig-Universität Giessen) and Philipps-University Marburg
(Ethikkommission des Fachbereichs Medizin der Philipps-Universität Marburg) approved the
use of human blood samples for this study. The participants provided their written consent to
participate in this study. The consent procedure was approved by the ethics committee.
BPI peptides
Purified BPI was purchased from Athens Research & Technology (Athens, Georgia, USA). The
peptides were synthesized by GeneScript (Piscataway, NJ, USA) and are listed in table 1. Except
the peptide for the active LL-37 which has an aa sequence as follows: LLGDFFRKSKEKIGKE
FKRIVQRIKDFLRNLVPRTES. All peptides had a purity of>95%.
Stimulation of human neutrophilic granulocytes
After sedimentation of erythrocytes from human buffy coats through 10 mL 6% Dextran T500
in 0.9% NaCl (Roth) for 20 min granulocytes were isolated by density gradient centrifugation
using Percoll PLUS (GE). Therefore, 5 mL of 5 x 107 cells/mL were overlaid on Percoll PLUS
gradient consisting of two layers. On the bottom 4 mL of 76% (1,099 g/mL) Percoll PLUS solu-
tion and 4 mL 61.5% (1,080 g/mL) Percoll PLUS-solution. The Percoll solution were prepared
in HBSS. Thereafter the cells were separated on the Percoll-gradient by centrifugation (700 x g,
30 min at room temperature) and the layer between 76% and 61.5% contained the granulocytes.
Table 1. BPI peptides used.
Name of the peptide amino acid sequence charge
huBPI-Peptid: NANIKISGKWKAQKRFLKMSGNFDLSI +5
mBPI-Peptid: DASIKINGKWMSRKNFLKAGGNFELSI +3
Mut.1 (1:N/D): DANIKISGKWKAQKRFLKMSGNFDLSI +4
Mut.2 (11:K/M): NANIKISGKWMAQKRFLKMSGNFDLSI +4
Mut.3 (1:N/D;11:K/M): DANIKISGKWMAQKRFLKMSGNFDLSI +3
Mut.4 (1:D/N;11:M/K): NASIKINGKWKSRKNFLKAGGNFELSI +5
Negative charged amino acids are marked in bold and positive charged amino acid are under-lined.
doi:10.1371/journal.pone.0156929.t001
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The cells were resuspended in RPMI complete (PAA Laboratories, Pasching, Austria) without
antibiotics and used for stimulation experiments. For the analysis of the purity of the isolated
granulocytes, fluorescein isothiocyanate-conjugated anti-CD66b monoclonal antibody (mouse
IgM, clone G10F5, BD Biosciences, Heidelberg, Germany) and, for macrophages, allophycocya-
nin-conjugated anti-CD14 monoclonal antibody (mouse IgG1, clone M5E2; BD Biosciences)
were used at 5 –l x 106 cells. Nonconjugated mouse IgG1 (clone MOPC-21; BD Biosciences)
was used as an isotype control. After Fc-binding sites were blocked to prevent unspecific bind-
ing, antibodies were applied for 20 min at 4°C for surface staining. After the cells were washed
with PBS-1% fetal calf serum, analysis was performed by flow cytometry. All flow cytometry
measurements were performed with a FACSCalibur cytometer using FlowJow and CellQuest
software (BD Biosciences).
To induce the degranulation of the granulocytes the cells were cultured in the presence of
purified Influenza A virus subtypes (H1N1, H3N2 and H5N1) (0.5, 1, 2, 4, and 8 MOI as deter-
mined by plaque test) or left unstimulated. After the indicated time points supernatant were
collected and the content of BPI in the supernatant was determined via ELISA.
The concentration of human BPI was determined via a specific ELISA as described else-
where (Aichele, 2006). Briefly, a rat-anti-mouse IgG monoclonal antibody (Bio-Rad AbD Sero-
tec, Puchheim, Germany) in 0,1 M NaHCO3 was coated overnight at 4°C followed by blocking
the wells with PBS/10%FCS containing a mouse anti-human BPI antibody (Hycult Biotechnol-
ogy, mAB HM2041) for 6 h at room temperature. Thereafter, standard (human BPI, Athens
Research & Technology) and samples were incubated overnight at 4°C. Finally, the detection of
the binding was determined by the incubation of a rabbit anti-human BPI antiserum (Hycult
Biotechnology, pAB HP9022) followed by a donkey anti-rabbit peroxidase coupled antiserum
(dianova, Hamburg, Germany). Each antibody was incubated for 2 h at room temperature. As
substrate TMB super sensitive (BioFX, Sur Modics, Eden Prairie, USA) was used and the reac-
tion was stopped by adding 1 M H3PO4 (pH 8.2). The OD was measured with an E max Preci-
sion Microplate Reader (Molecular Devices, Biberach, Germany) at 450 nm and analyzed with
the „Softmax Pro”software.
Viruses and electron microscopy
Influenza A-Virus strain A/PR/8/34 (H1N1) was purified from the allantois fluid. The strains
A/Aichi/2/68 (H3N2) and rg A/Vietnam//1203/04 (H5N1) [16] were purified from cell culture
supernatants of infected BHK cells. The IAV strain rg A/Vietnam//1203/04 (H5N1) harbours
only hemagglutinin as well as neuraminidase form H5N1 and the rest of the virus is of strain
A/PR/8/34 origin. The IAV clinical isolate H5N1 is the previously described virus A/Thailand/
1(Kan-1)/2004 strain [17]. Measles virus strain Edmonston was obtained from the cell culture
supernatant of infected Vero cells and VSV-GFP was propagated in HeLa cells and purified by
dense gradient centrifugation.
For negative staining, purified virus particles were fixed in 1 x PBS containing 6% (v/v)
formaldehyde. 5μL particle solution was applied to carbon coated 400 mesh copper grids.
Grids were washed twice with distilled water and negatively stained with 2% (w/v) uranyl-ace-
tate for 30 sec. Transmission electron microscopy was carried out using a JEOL TEM 2100 at
120kV. Micrographs were recorded with a fast-scan 2k x 2k CCD camera F214 (TVIPS, Gaut-
ing, Germany).
MDCK infection and detection of the virus
Protease-deficient MDCK(H) cells [18] were infected with 500 PFU/well Influenza A virus
strain APR8 (H1N1) or Aichi (H3N2) or Vietnam (H5N1) or Thailand (H5N1) for 1 h. These
BPI and Influenza
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cells are not able to produce infectious virus particles and therefore a single infection cycle can
be detected. Before the infection the virus was incubated in the presence or absence of the indi-
cated amount of human BPI-peptide or control peptides for 1 h. After the infection the super-
natant was replaced by growing media and the cells were incubated for additional 13 h except
for Thailand (H5N1) which was incubated for 8 h. Thereafter, the multiplied virus could be
visualized inside the infected cells by the detection of the viral nucleoprotein. Prior to the stain-
ing the cells were fixed with 4% paraformaldehyde and permeabilized with 0.3% of Triton-X-
100. After that the fixed and permeabilized cells were incubated with the mouse anti–nucleo-
protein IAV monoclonal antibody [19]. The binding of the antibody was detected by a second-
ary antibody coupled to HRP (donkey anti-mouse IgG-HRP, dianova) and adding of the
reagent TMB Super Sensitive One Component HRPMicrowell Substrate (BioFX). Colour
development was stopped by adding 1 M H3PO4 and detected with an E max Precision Micro-
plate Reader (Molecular Devices) at 450 nm and analyzed with the „Softmax Pro”software.
Plaque test for VSV
BHK-21 cells (ATCC HTB-55) were infected with 360 PFU/well of VSV-GFP virus. Prior to
infection the VSV was incubated with 20 μg/mL of human BPI and mouse BPI-peptide, respec-
tively or remained untreated for 1 h. After 1.5 h of infection the virus was removed and the
cells were overlaid with MEMmedium containing penicillin and streptomycin, 1% L-Gluta-
mine, 10% FCS and 1.25% Avicel (Sigma-Aldrich). The cells were incubated for 42 h. Thereaf-
ter, the supernatant was removed from the cells and the cells were fixed with 10% of
formaldehyde at 4°C for 1 h and stained with 0.1% crystal violet for 1 h at 4°C after washing of
the formaldehyde. After extensive washing of the excessive crystal violet the plaques were
counted.
Infection of Calu3 cells with IAV
50–70% confluent Calu-3 cells (ATCC CCL-10) were infected with 300 PFU/well Influenza A
virus strain A/Aichi/2/68 (H3N2). Prior to the infection the virus was incubated in the presence
or absences of the indicated amount of human or mouse BPI-peptide for 1 h. Thereafter, the
virus solution was removed and the cells were incubated for 24, 48, 72, and 96 h. The virus
amount in the supernatant was analysed by adding an aliquot of the supernatant to MDCK (H)
cells and performing the detection of the virus as outlined above in the part MDCK infection
and detection of the virus. Furthermore, also the release of CCL5 into the supernatant of the
infected Calu-3 cells was determined via a specific ELISA as recommended by the manufac-
turer (Peprotech, Hamburg, Germany). The OD was measured with an E max Precision Micro-
plate Reader (Molecular Devices) at 450 nm and analyzed with the „Softmax Pro”software.
Isolation of PBMCs and stimulation
Human PBMCs were isolated by dense gradient centrifugation from buffy coats. Briefly, cells
from the buffy coat were pipetted onto lymphocyte separation medium (Ficoll-solution; 1,077
g/mL, PAA) and centrifuged at 670 x g for 30 minutes at room temperature (20°C). The upper
layer contained the PBMCs. The cells were resuspended in RPMI complete substituted with 2%
of AB serum (human serum of blood group AB positive). Thereafter, the cells were seeded and
stimulated with LPS (100 ng/mL, Sigma-Aldrich), CpG 2216 (2 μM, Biomers, Ulm, Germany),
purified influenza A virus (MOI 2) in the presence and absence of human and mouse BPI-pep-
tides, and left unstimulated. After 20 h the supernatant was collected and the release of IFNα
was determined by a specific ELISA.
BPI and Influenza
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Therefore, anti-human IFNα coating antibody (BenderMedSystems, Wien, Austria) was
used to coat a microtiter plate and the binding of recombinant IFNα (Peprotech) as standard
or the samples were detected by a secondary anti-human-IFNαHRP-conjugated antibody
(BenderMedSystems). For the detection of human IL-6 the coupling of the microtiter plate was
performed with anti-human IL-6 coating antibody (R&D Systems,Wiesbaden, Germany). As
standard recombinant human IL-6 (RD Systems) was used and the binding was detected by a
secondary anti-human-IL-6 Biotin-conjugated antibody ((R&D Systems), followed by Strepta-
vidin-HRP. As substrate TMB super sensitive (BioFX, Sur Modics) was used and the reaction
was stopped by adding 1 M H3PO4 (pH 8.2). The OD was measured with an E max Precision
Microplate Reader (Molecular Devices) at 450 nm and analyzed with the „Softmax
Pro”software.
Statistics
Statistical significance was analysed using Prism 4.01 GraphPad1 software. Means and the
respective standard deviations (SD) were calculated. Significance was tested by unpaired Stu-
dent‘s-t-test.  are P values< 0.05;  are P values< 0.01,  are P values< 0.001.
Results
IAV induces the release of BPI from human granulocytes
To determine whether the stimulation of neutrophilic granulocytes with the Influenza A virus
strains H1N1 (Fig 1A), H3N2 (Fig 1B) as well as IAV strain rg A/Vietnam//1203/04 harbour-
ing hemagglutinin and neuraminidase from H5N1 (Fig 1C) would result in the release of BPI
from the azurophilic granules of these cells we isolated human neutrophilic granulocytes form
buffy coats. Usually the cells had a purity of greater than>95% as judged by flow cytometry
(data not shown). These cells were stimulated in the presence of 0.5–8 MOI of the indicated
purified IAV strains. After 4 as well as 16 hours of stimulation the incubation of the neutrophils
with virus resulted in the enhanced release of BPI (Fig 1).
BPI inhibits the activation of PBMCs by IAV
Since we observed an enhanced release of BPI from neutrophils after the interaction with IAV
obtaining a strong response with a MOI 2 we asked whether BPI would influence the stimula-
tion capacity of the virus. Therefore, we isolated human PBMCs from buffy coats and stimu-
lated the cells in the presence of MOI 2 of purified Influenza A virus (H1N1). The virus were
pre-incubated with increasing amounts of human BPI-peptide for 30 min, which was previ-
ously shown to harbour antibacterial activity [20], or with the respective homologous mouse
BPI-peptide and added to the cells thereafter. After 20 h of infection the supernatant was col-
lected and analysed via an IFNα as well as an IL-6 ELISA. Only the pre-incubation of IAV with
human BPI-peptide did inhibit the release of IFNα (Fig 2A) as well as IL-6 (Fig 2B) from these
cells in a dose dependent manner whereas the mouse BPI-peptide homolog did not show this
effect. From this experiment we concluded that the human BPI-peptide does interfere with
IAV infectivity
BPI inhibits the infectivity of IAV
To get a first insight at what level of the infection cycle human BPI does interfere with IAV we
chose a single round infection model. Thereby, MDCK cells harbouring a protease deficiency
which will not release virus after infection were infected with 500 PFU/well IAV in the presence
or absence of different peptides derived from human or mouse BPI, respectively. Therefore
BPI and Influenza
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Fig 1. Influenza A virus induces the release of BPI from human granulocytes. After Dextran
sedimentation granulocytes were isolated from human buffy coats by density gradient centrifugation. After
the control of the purity of the collected neutrophils by the measurement of the surface expression of CD14
and CD66 using flow cytometry the degranulation of the granulocytes were induced in the presence of
purified Influenza A virus subtypes A) H1N1, B) H3N2 and C) H5N1 (0.5, 1, 2, 4, and 8 MOI, black bar) or left
unstimulated (white bar). The IAV strain rg A/Vietnam//1203/04 (H5N1) harbours only hemagglutinin as well
as neuraminidase form H5N1 and the rest of the virus is of strain A/PR/8/34 origin. After 4 as well as 16 hrs of
stimulation the supernatants were collected and the content of BPI in the supernatant was determined via
ELISA. Three experiments with similar results were performed and one representative is shown. Statistically
significant differences are given as p values (** <0.01); n = 3 ± SEM.
doi:10.1371/journal.pone.0156929.g001
BPI and Influenza
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MDCK cells were infected with Influenza A virus strain A/PR/8/34 (H1N1) (A) and strain A/
Aichi/2/68 (H3N2) (B) for 1 h. After the infection the virus containing supernatant was
removed and the cells were grown for additional 13 h. We could demonstrate that human BPI-
peptide specifically was able to inhibit the infection of MDCK cells since the mouse BPI-derived
Fig 2. Human BPI-peptide inhibits the activation of PBMCs by Influenza A virus.Human PBMCs were
isolated by dense gradient centrifugation from buffy coats. Thereafter, the cells were seeded and stimulated
with purified Influenza A virus (MOI 2) (H1N1) in the presence (black bars) of increasing concentrations and
absence (white bar) of human and mouse BPI-peptides (50 μg/mL, (grey bar)), and left unstimulated (control).
In addition, the cells were incubated in the presence of either human BPI-peptide (50 μg/mL, huBPI) or mouse
BPI-peptide (50 μg/mL, mBPI), respectively. After 20 h the supernatant was collected and the release of IFNα
(A) as well as IL-6 (B) was determined by a specific ELISA. One representative experiment out of three is
displayed. Statistically significant differences are given as p values (* <0.05 and ** <0.01); n = 3 ± SEM.
doi:10.1371/journal.pone.0156929.g002
BPI and Influenza
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homologous peptide had no effect (Fig 3A). Additionally we could demonstrate that human
BPI-peptide did inhibit the infectivity of different subtypes of IAV (Fig 3A for H1N1 and Fig 3B
for H3N2; H5N1 both IAV strain rg A/Vietnam//1203/04 harbouring hemagglutinin and neur-
aminidase fromH5N1, S1A Fig, as well as a clinical H5N1 isolate, S1B Fig).
After the inhibition of the IAV infection of MDCK-cells we analysed whether BPI might
also inhibit the infection of the human lung epithelial cell line Calu3 with IAV. Therefore, IAV
(H3N2) were incubated in the presence of either human or mouse BPI-peptide prior to infect
Calu3 cells for 1 h. Thereafter, the virus solution was removed and the cells were incubated for
24 h. We were not able to detect endogenous BPI in the supernatant of IAV infected Calu3
cells (data not shown). In addition, after overnight incubation the virus titer was determined
by plating serial dilutions of the supernatant on MDCK cells. As shown in Fig 3C the human
BPI peptide did also inhibit the infectivity of the primary IAV target cells during infections
resulting in strongly diminished virus titer. In accordance to the virus particle data human
BPI-peptide did also inhibit the release of the chemokine CCL5 into the supernatant of the
infected Calu3 cells (Fig 3D).
BPI does not induce an antiviral status in the target cells
First we were interested whether human BPI peptide would act stronger when it was incubated
for longer time periods before we added IAV (H1N1) to the target cells. We could not observe
an enhanced antiviral activity of human BPI-peptide when we prolonged the virus-peptide
interaction time up to 4 h (Fig 4A).
Furthermore, to get a first hint in the mechanistic action of the human BPI peptide we incu-
bated the MDCK (H) cells with the human BPI peptide for 1 h before the peptide was removed
and the cells were infected (IAV H1N1). This experimental setting did not lead to an inhibition
of viral replication in the target cells (Fig 4B). We were also not able to detect the release of
type I IFN from the MDCK (H) cells after peptide incubation without virus infection (data not
shown). From this experiment we concluded that human BPI-peptide did not induce an antivi-
ral status in MDCK (H) cells and therefore, the peptide might directly interact with the virus
particles.
BPI inhibits the replication of VSV
In order to analyze whether the action of the BPI-peptide was specific towards IAV we investi-
gated the activity of the BPI-peptide against VSV infectivity. As depicted in Fig 5A we could
show that the human BPI-peptide did inhibit the infectivity of VSV particles in a plaque test
with BHK cells. Furthermore, we could not show that human BPI-peptide was able to inhibit
the infectivity of HIV or measles virus (S2 and S3 Figs). However an inhibitory effect of human
BPI against HIV could be observed (S2A Fig) but this inhibitory effect of the human BPI pep-
tide at higher concentrations (100 and 20 μg/mL) could be attributed to the toxic effects of the
peptide against the cell line used in this experiment (S2B Fig).
To get a first insight why the human BPI-peptide displayed antiviral function in comparison
to the mouse homologue we compared the sequences of both peptides. Thereby we noticed
that differences in the amino acid sequences between mouse and man resulted in changes in
the overall charge of the peptides. Whereas the human peptide has a charge of +5 the mouse
peptide has an overall charge of +3. Therefore, we inserted two mutations separately and in
combination to the human peptide, which resulted in the decrease of the charge in the double
mutant peptide to +3 (Table 1). As shown in the Fig 5B both mutations separately resulted in
no reduction of the activity of the human peptide but the combined mutations in the human
BPI-peptide led to a loss of great proportions of its activity against Influenza A virus (H3N2)
BPI and Influenza
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Fig 3. Human BPI-peptide specifically inhibits the replication of different IAV strains. Protease-deficient MDCK(H) cells were infected with
500 PFU/well of Influenza A virus strain A/PR/8/34 (H1N1) (A) and strain A/Aichi/2/68 (H3N2) (B) for 1 h. After the infection the virus containing
supernatant was removed and the cells were grown for additional 13 h. Thereafter, the fixed and permeabilized cells were incubated with the
mouse anti–nucleoprotein IAV monoclonal antibody. The binding of the antibody was detected by a donkey anti-mouse IgG-HRP antiserum and
adding the reagent TMB Super Sensitive One Component HRPMicrowell Substrate. Substrate conversion was detected by 450 nm. For the
control sample is n = 8 ± SEM, all other samples n = 5 ± SEM. C) Calu-3 cells were infected with 300 PFU/well of Influenza A virus strain A/Aichi/2/
68 (H3N2). Prior to the infection the virus was incubated in the presence or absences of the indicated amount of human or mouse BPI-peptide for
BPI and Influenza
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(Fig 5B). Furthermore, an additional mouse peptide was generated which displayed the charge
of the human wild type peptide (Table 1). The mutation of the previously inactive mouse BPI
peptide in a way that it has the same charge as human BPI peptide (+5) is sufficient to convert
the mouse BPI into an antiviral active peptide (Fig 5C).
BPI modifies the structure of IAV particles
To get an insight of the action of the BPI peptide against IAV we analyzed the potential of
human BPI peptide to inhibit the haemagglutination or hemolysis effects of Influenza A virus.
We could not find a meaningful inhibition of either the haemagglutination or hemolysis activ-
ity of Influenza A virus in the presence of human BPI peptide (S4 and S5 Figs). To further ana-
lyse the potential mechanism of action of the human BPI peptide we investigated the virus
particles after incubation with the peptides either with 100 (100) and 500 μg/mL (500) of
human or murine BPI-peptides for 1 h or left untreated by transmission electron microscopy
(Fig 6). After incubation with 500 μg/mL of the human BPI-peptide clear visible structural
alterations of the virus particles could be observed as these seem to lack their virus envelope
and therefore, only breakdowns of the particles were visible. At lower concentrations the
human BPI-peptide induced the virus capsid to bulge which is, however, still clearly visible
(arrows in Fig 6). This phenomenon was described for the action of HNP-1 an antimicrobial
peptide of the α-defensin family against papillomavirus [21]. In contrast, after incubation with
the mouse BPI-peptide no structural changes of the virus capsid could be observed. A similar
experimental setup for VSV did not result in visible damage of the virus envelope after incuba-
tion with human BPI peptide (S6 Fig).
Discussion
Human BPI displays a very well characterized antimicrobial activity against various gram nega-
tive bacteria. We could recently demonstrate that a 27 aa acid peptide derived from the N-ter-
minal part of the protein is able to inhibit the growth of even multi resistant Pseudomonas
aeruginosa very efficiently [20]. Moreover, the protein of mouse and human BPI neutralizes
Lipopolysaccharide from the cell wall of gram negative bacteria with similar efficiency [22].
Most likely the killing of the bacteria results from the interference of the BPI with the cell wall
of the bacteria which finally leads to an osmolaric instability of the bacterial membrane [23].
We extend the activity of human BPI to IAV as well as VS-virus. As shown by electron micros-
copy this happens most likely by the interaction of the BPI-peptide with the virus particle lead-
ing to direct damage of the envelope of the virus particles. This however does neither result in
the inhibition of the haemagglutination activity nor in the hemolysis capacity of Influenza A
virus. Since we were not able to demonstrate antiviral activity against HI-virus envelope this
activity displays some sort of specificity. What exactly determines this specificity is currently
unknown.
The principle activity of defensins against viruses was demonstrated before. There is an
increasing body of evidence that AMPs act against a variety of viruses. For example α-defensins
were shown to inhibit infections mediated by papillomavirus [21], neutralize adenovirus [24]
1 h. Thereafter, the virus solution was removed and the cells were incubated for 24 h. The virus amount in the supernatant was analysed by
adding an aliquot of the supernatant to MDCK (H) cells for 1 h. After the infection the virus containing supernatant was removed and the cells were
grown for additional 13 h. Thereafter, the fixed and permeabilized cells were incubated with the mouse anti–nucleoprotein IAV monoclonal
antibody and detected as outlined above. (D) Furthermore, also the release of CCL5 into the supernatant of the infected Calu-3 cells was
determined via a specific ELISA. One representative experiment out of 5 performed is displayed. Statistically significant differences are given as p
values (** <0.01 and *** <0.001); n.s. is not significant; n = 3 ± SEM.
doi:10.1371/journal.pone.0156929.g003
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Fig 4. Human BPI-peptide acts not via a cell autonomous pathway. Protease-deficient MDCK(H) cells
were infected with 500 of PFU/well Influenza A virus strain A/PR/8/34 (H1N1) for 1 h. Before the infection the
virus was incubated in the presence or absence of the indicated amount of human BPI-peptide or control
peptides for 1 h up to 4h (A). After the infection the virus containing supernatant was removed and the cells
were grown for additional 13 h. Thereafter, the fixed and permeabilized cells were incubated with the mouse
BPI and Influenza
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and inhibit the fusion of HIV with PBMCs [25]. Mechanistically, it was demonstrated that the
entering of HIV into its target cells was inhibited by HNP-1 at multiple steps. First the binding
of the virus to its co-receptor (CCR5 und CXCR4) was blocked. Second the endocytosis of the
virus into the target cell was inhibited and finally the release of the HIV -genome from the
endosome into the cytoplasm was blocked. HNP-1 binds to the N-terminal part of the primary
cellular receptor of HIV, namely CD4 preventing thereby the interaction of the virus with the
co-receptor. At the same time HNP-1 binds to the trimeric Env of the virus [13]. Importantly
the endocytosis of Influenza A virus could not be inhibited by HNP-1. On the other hand an
antiviral activity against Influenza A virus mediated by HNP-1was published before [26]. The
antiviral effect in this study most likely was due to the activation of the target cells with the pep-
tide rather than a direct activity against the virus particles. We, however, did not observe any
activation of the cells, e.g. granulocytes, PBMCs as well as MDCK cells by the BPI-peptides in
this study. Instead we clearly demonstrate a direct effect on the virus envelope. The induction
of the release of AMPs including BPI by Influenza A virus directly acting against the incoming
thread might be a mechanism how the immune system restricts the infection at an early stage
during the infection process and may limit pathogenicity of the pathogen.
Furthermore, the cathelicidin LL-37 was shown to inhibit the infectivity of HIV. From LL-
37 it is known that it binds to the cellular formyl-peptide receptor 1 (FPRL-1) and mediate che-
motaxis, immunomodulatory activity as well as angiogenic functions enabling LL-37 to activate
the immune system [27]. However the anti-HIV activity was independent on the FPRL-1 [28].
Moreover LL-37 by as yet unknown reasons acts against adenovirus and Herpes simplex virus
1 and 2, respectively [29,30]. In another article the cathelicidin had direct effects on the virion
structure of vaccinia virus as judged by transmission electron microscopy [31]. Finally, LL37
influenced the infectivity of Influenza A virus and the application of LL-37 to mice prevented
or inhibited the infection with Influenza A virus in an infection model [12]. The molecular
mechanism of how LL-37 leads to the reduced infectivity of the virus was not analyzed. Fur-
thermore, the spectrum of the antiviral potency of LL-37 was not determined.
Another aspect of our study shows that the antiviral activity of the peptide is determined by
the charge of the peptide. This corroborates our findings that the peptides directly damage the
virus envelope. To do so the peptides need to directly interact and may bind to the virus enve-
lope and therefore the charge of the peptide is an important determinant of this interaction.
This is also known for the antimicrobial activity of the defensins and BPI as well. Due to the
cationic nature of the AMPs these proteins are able to insert into the anionic charged bacterial
membrane where they are able to make wholes into the cell membrane leading to an osmolaric
instability of the bacteria [32]. Modifications of AMPs lead to changes in their tertiary structure
and providing antimicrobial activity. This was shown for the β-defensin HBD-3. Reduction of
the disulphate bonds in HBD-3 through the action of thioreductase unmasks its antimicrobial
potential [32]. This shows that changes in the three-dimensional structure of an AMP deter-
mines the antimicrobial potential. In addition the subtle changes in the charge of the peptides
resulted also in the gain or loss of activity. Further analysis especially in infection models might
anti–nucleoprotein IAV monoclonal antibody. The binding of the antibody was detected by a donkey anti-
mouse IgG-HRP antiserum and adding of the reagent TMB Super Sensitive One Component HRPMicrowell
Substrate at 450nm. (B) MDCK (H) cells were preincubated with the indicated amount of peptides for 1 h.
Thereafter the supernatant of the cells was removed and the cells were infected with 500 PFU/well Influenza A
virus strain A/PR/8/34 (H1N1) for 1 h. Subsequently the infection and detection of the virus was performed as
described above. One representative experiment out of 3 performed is displayed. One representative
experiment out of 3 performed is shown. Statistically significant differences are given as p values (*** <0.001);
n = 5 ± SEM.
doi:10.1371/journal.pone.0156929.g004
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Fig 5. Mutant human BPI-peptide corresponding to the mouse peptide loose its activity and human BPI peptide inhibits the replication of VSV.
BHK-cells were infected with 360 PFU/well of VSV-GFP virus. Prior to infection the VSV was incubated with 20 μg/mL of human BPI (huBPI) and mouse
BPI-peptide (mBPI), respectively or remained untreated (control) for 1 h. After 1.5 h of the cells were overlaid with 1.25% Avicel medium and incubated for
42 h. Thereafter, the cells were fixed and stained with crystal violet for 1 h at 4°C. Finally the plaques were counted (A). MDCK(H) cells were infected with
500 PFU/well Influenza A virus strain A/PR/8/34 (H1N1) for 1 h. Before the infection the virus was incubated in the presence or absence of 20 μg/mL of
either human BPI-peptide (huBPI), murine BPI-peptide (mBPI), human BPI-peptide N1D (mutant 1), human BPI-peptide K11M (mutant 2), human BPI-
peptide N1D and K11M (mutant 3) or left untreated (control) for 1 h (B) or incubated in the presence or absence of 20 μg/mL of either human BPI-peptide
(huBPI), murine BPI-peptide (mBPI), mouse BPI-peptide D1N and M11K (mutant 4) or left untreated (control) for 1 h (C). After the infection the virus
containing supernatant was removed and the cells were grown for additional 13 h. Thereafter, the fixed and permeabilized cells were incubated with the
mouse anti–nucleoprotein IAV monoclonal antibody. The binding of the antibody was detected by a donkey anti-mouse IgG-HRP antiserum and adding of
the reagent TMB Super Sensitive One Component HRPMicrowell Substrate. Substrate conversion was detected by 450 nm. One representative
experiment out of 3 performed is shown. Statistically significant differences are given as p values (*** <0.001); n.s. is not significant; n = 5 ± SEM.
doi:10.1371/journal.pone.0156929.g005
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demonstrate whether peptides derived prom BPI displaying anti-viral activity can serve as
alternatives in the future to treat infections with IAV. Furthermore the requirements in the
sequence or the structure of such peptides might help to predict and design potential peptides
with anti-viral effects. This might be of particular interest in the setting were treatment with
conventional anti-IAV medication is not working due to mutations in the virus genome.
Supporting Information
S1 Fig. Human BPI-peptide specifically inhibits the replication of Influenza-A Vietnam
(H5N1). Protease-deficient MDCK(H) cells were infected with 500 PFU/well of Influenza
A-Virus strain A Vietnam (H5N1) for 1 h. A) The IAV strain rg A/Vietnam//1203/04 (H5N1)
harbours only hemagglutinin as well as neuraminidase form H5N1 and the rest of the virus is
of strain A/PR/8/34 origin and B) the IAV strain A/Thailand/1(Kan-1)/2004 strain (H5N1).
After the infection the virus containing supernatant was removed and the cells were grown for
additional 13 h in case of Vietnam (H5N1) and 8 h for Thailand (H5N1). Thereafter, the fixed
and permeabilized cells were incubated with the mouse anti–nucleoprotein Influenza A mono-
clonal antibody. The binding of the antibody was detected by a donkey anti-mouse IgG-HRP
antiserum and adding the reagent TMB Super Sensitive One Component HRP Microwell Sub-
strate. Substrate conversion was detected by 450 nm. S ample number n = 5 ± SEM. One
Fig 6. Human BPI-peptide damages the IAV particles. Virus particles were incubated either with 100 (100) and 500 μg/
mL (500) of human (A) or murine BPI-peptides (B) for 1 h or left untreated (C). After the incubation the virus particles were
visualized by transmission electron microscopy. Therefore, the particles were negatively stained with 2% uranylacetate
and transmission electron microscopy was carried out using a JEOL TEM 2100 at 120kV. Micrographs were recorded with
a fast-scan 2k x 2k CCD camera F214. One representative experiment out of 3 performed is displayed.
doi:10.1371/journal.pone.0156929.g006
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representative experiment out of 3 performed is displayed. Statistically significant differences
are given as p values ( <0.01 and  <0.001); n.s. is not significant.
(TIF)
S2 Fig. Human BPI peptide does not inhibit the infectivity of HIV. Growth kinetics of HIV-
1 in the presence of BPI. C8166 cells were infected and cultured in the presence of various con-
centrations of human (A) and mouse (B) BPI. Samples taken at various time-points were
assayed for levels of HIV-1 Gag p24 by antigen-capture ELISA. The apparent inhibitory effect
seen with the human BPI at 100μg/mL (and partially with 20 μg/mL) was the result of the high
cytopathic effect of the human BPI peptide at these concentrations, even in the absence of
HIV.
(TIF)
S3 Fig. Human BPI peptide does not inhibit the infectivity of measles virus. 500 Pfu/well
Measles virus and peptides were incubated for 1 h in a 96-well plate and thereafter Protease-
deficient MDCK(H) cells were added to the virus peptide solution and incubated for additional
13 h. After that the fixed and permeabilized cells were incubated with the mouse anti–measles
matrixprotein monoclonal antibody. The binding of the antibody was detected by a secondary
antibody coupled to HRP (donkey anti-mouse IgG-HRP) and adding of the reagent TMB
Super Sensitive One Component HRP Microwell Substrate. Substrate conversion was detected
by 450 nm. Sample number n = 5 ± SEM. One representative experiment out of 3 performed is
displayed.
(TIF)
S4 Fig. Human BPI does not inhibit haemagglutination activity of Influenza A virus. 500
PFU/well of the IAV strains A/PR/8/34 (H1N1), strain A/Aichi/2/68 (H3N2) or strain rg A/
Vietnam//1203/04 (H5N1) were incubated with 100 μg/mL of the indicated peptide for 1 h.
Thereafter, 2-fold serial dilution of the peptide virus samples were made and an equal volume
of 1% sheep erythrocytes were added and incubated on ice for additional 1 h. After the incuba-
tion time pictures of the plate were taken to visualize the haemagglutination properties of the
virus. One representative experiment out of 3 performed is shown.
(TIF)
S5 Fig. Human BPI does not inhibit the hemolysis effects of Influenza A virus. 500 PFU/
well of the IAV strain A/Aichi/2/68 (H3N2) were incubated with 100 μg/mL of the indicated
peptide (human BPI peptide huBPI (black triangle), mouse BPI peptide mBPI (black triangle
upside down)) or left untreated (control (black square)) for 1 h. To adjust for the autofluores-
cence of the erythrocytes they were included in the measurement as negative control (negative
(black diamond)). Thereafter, the peptide virus solution was added to 1% hematocrit of human
erythrocytes and hemolysis was induced by shifting the pH to 5 with PBS/citric acid solution.
The amount of hemolysis was measured in the supernatant after 20 min incubation at 37°C at
an OD 405 nm A). In B) the direct effects of the peptides towards the erythrocytes was analyzed
essentially as in A) but leaving the virus out. Sample number n = 9 ± SEM. One representative
experiment out of 3 performed is displayed.
(TIF)
S6 Fig. Human BPI-peptide does not damage VSV particles. Virus particles were incubated
either with 500 μg/mL (500) of human (A) or murine BPI-peptides (B) for 1 h or left untreated
(C). After the incubation the virus particles were visualized by transmission electron micros-
copy. Therefore, the particles were negatively stained with 2% uranylacetate and transmission
electron microscopy was carried out using a JEOL TEM 2100 at 120kV. Micrographs were
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recorded with a fast-scan 2k x 2k CCD camera F214. One representative experiment out of 3
performed is displayed.
(TIF)
S1 File. Supplemental methods.
(DOCX)
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